Abstract: Embodiments of the present invention relate to data detection technologies, and in particular, to a method and an apparatus for detecting time series data. A method for detecting time series data is disclosed. The method is applied to a data transmission system and includes: determining, based on data information carried in time series data from a data source device, whether missing of time series data occurs in a data receiving process, where the data information includes time information and/or sequence numbers; if missing of time series data occurs, storing data information of the missing time series data; determining whether a preset trigger condition for a data missing notification is currently satisfied; and if the trigger condition for a data missing notification is satisfied, sending data missing notification information to a target device.

Abstract: A full recovery, recycling and regenerative method includes the polyester fibers being interwoven with elastic polyurethane fibers or elastic polyolefin fibers, or blended with regenerated cellulose fibers such as cotton, linen and viscose, by using titanium easily decomposed and recycled polyesters, and the complete separation of the fibers or blended fibers of the polyester fibers and the elastic fibers being achieved using the differences in chemical resistance and temperature resistance of various components. The polyester can be decomposed into small molecules under mild conditions of hydrolysis, alcoholysis and alkali hydrolysis. Under such mild conditions, the elastic polyurethane or elastic polyolefin fibers, or fibers such as the cotton, the linen, the viscose and nylon, are resistant to hydrolysis or alcohol, and will not decompose. The separation of the polyester fibers from other components is achieved. The other separated components are single loose components which can be recycled.

Abstract: The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

Abstract: The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

Abstract: The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

Abstract: An array substrate, a display panel, and a display device are provided. The array substrate comprises a plurality of pixel regions in an array along intersected first and second directions. The pixel region includes at least three subpixel regions. At least one subpixel region serves as an adjustment-subpixel region. The subpixel region has a first electrode including at least two parallel first straight portions. Second straight portions and first connecting portions are connected to first and second ends of the first straight portions, respectively. The first electrode corresponding to the adjustment-subpixel region serves as an adjustment electrode. An opening is configured at an end between the at least two adjacent second straight portions corresponding to the adjustment electrode. An angle between extending direction of the first straight portion and the second direction is less than an angle between extending direction of the second straight portion and the second direction.

Abstract: The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.

Abstract: A backlight module and a display device are provided. The backlight module includes a backing plate. The backing plate includes a first surface and a second surface disposed oppositely to the first surface. First surface of the backing plate includes a first region and a second region surrounding the first region. The backlight module also includes a plurality of light sources disposed on the first surface of the backing plate and arranged in an array. The plurality of light sources includes a plurality of first light sources in the first region and a plurality of second light sources in the second region. The backlight module also includes a plurality of reflection structures. Each of the reflection structures is disposed at periphery of one second light source, and reflects light emitted by the second light source to a side of the second light source facing away from the backing plate.

Abstract: The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

Abstract: The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

Abstract: A backlight module and a display device are provided. The backlight module includes a backing plate. The backing plate includes a first surface and a second surface disposed oppositely to the first surface. First surface of the backing plate includes a first region and a second region surrounding the first region. The backlight module also includes a plurality of light sources disposed on the first surface of the backing plate and arranged in an array. The plurality of light sources includes a plurality of first light sources in the first region and a plurality of second light sources in the second region. The backlight module also includes a plurality of reflection structures. Each of the reflection structures is disposed at periphery of one second light source, and reflects light emitted by the second light source to a side of the second light source facing away from the backing plate.

Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

Abstract: The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

Abstract: The present disclosure provides an array substrate and a display panel containing the array substrate. The array substrate includes a plurality of pixel regions, and pixel electrodes and thin film transistors one-to-one corresponding thereto. Each pixel electrode includes a pixel sub-electrode and an electrode connecting structure disposed in a corresponding pixel region, and a drain electrode of each thin film transistor is electrically connected to a corresponding pixel sub-electrode. The plurality of pixel regions includes at least one first-color pixel region and at least one second-color pixel region alternately arranged along a first direction and at least one third-color pixel region and at least one highlight pixel region alternately arranged along a first direction. A drain electrode is electrically connected to a pixel sub-electrode disposed in one of the at least one third-color pixel region is disposed in a highlight pixel region adjacent to the third-color pixel region.

Abstract: The present disclosure relates to a liquid crystal display panel and a display device. The liquid crystal display panel includes a display area; and a non-display area surrounding the display area, wherein the display area includes a plurality of sub-areas, each of the plurality of sub-areas is provided with a plurality of pixel electrodes, all of the pixel electrodes in a sub-area have an identical brightness control parameter; and the brightness control parameter of the pixel electrodes in at least one sub-area is different from the brightness control parameter of the pixel electrodes in another sub-area. By setting different brightness control parameters based on different temperature rise in the sub-areas, the problem of poor Gamma uniformity of the display panel can be solved, and the possibility of occurrence of ghost can be reduced, thereby increasing display quality of the liquid crystal display panel.

Abstract: The invention discloses a method for preparing a hollow textile with a core-spun yarn of short-staple wrapped microporous alkali-soluble polyester filament, which includes a foaming microcapsule preparation step, a preparation step of alkali-soluble chips containing foaming microcapsules, a melt foaming and spinning step, and a hollow textile preparation step. In the method for preparing the hollow textile with the core-spun yarn of short-staple wrapped microporous alkali-soluble polyester filament, a hollow yarn or a hollow fabric is made from a polyester filament having a microporous structure through alkali dissolution. The polyester filament having a microporous structure can effectively increase the contact area of the alkali dissolution and has the advantages of high dissolution rate, short dissolution time and complete dissolution.

Abstract: The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

Abstract: The present disclosure provides an array substrate and a display panel containing the array substrate. The array substrate includes a plurality of pixel regions, and pixel electrodes and thin film transistors one-to-one corresponding thereto. Each pixel electrode includes a pixel sub-electrode and an electrode connecting structure disposed in a corresponding pixel region, and a drain electrode of each thin film transistor is electrically connected to a corresponding pixel sub-electrode. The plurality of pixel regions includes at least one first-color pixel region and at least one second-color pixel region alternately arranged along a first direction and at least one third-color pixel region and at least one highlight pixel region alternately arranged along a first direction. A drain electrode is electrically connected to a pixel sub-electrode disposed in one of the at least one third-color pixel region is disposed in a highlight pixel region adjacent to the third-color pixel region.

Abstract: An array substrate, a display panel, and a display device are provided. The array substrate comprises a plurality of pixel regions in an array along intersected first and second directions. The pixel region includes at least three subpixel regions. At least one subpixel region serves as an adjustment-subpixel region. The subpixel region has a first electrode including at least two parallel first straight portions. Second straight portions and first connecting portions are connected to first and second ends of the first straight portions, respectively. The first electrode corresponding to the adjustment-subpixel region serves as an adjustment electrode. An opening is configured at an end between the at least two adjacent second straight portions corresponding to the adjustment electrode. An angle between extending direction of the first straight portion and the second direction is less than an angle between extending direction of the second straight portion and the second direction.

Abstract: The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.